Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

Previously vaccinated children from 12 months of age, adolescents and adults NimenrixTM may be given as a booster dose to individuals who have previously received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see section 5.1).

2014年4月4日 · Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection ...

2024年10月24日 · CDC recommends meningococcal vaccination for all adolescents. CDC also recommends meningococcal vaccination for children and adults at increased risk for meningococcal disease. Follow the recommended immunization schedule to ensure that your patients get the meningococcal vaccines that they need.

In June 2012, the FDA approved a combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, prevents disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.

Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis

NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Information. Product Monograph (download PDF, 429KB) Patient Information (download PDF, 94KB) Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means.

Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called “Neisseria meningitidis" types A, C, W-135 and Y. “Neisseria meningitidis" types A, C, W-135 and Y bacteria can cause serious illnesses such as: • meningitis - an infection of the tissue that lines the brain and spinal cord.

Details for Nimenrix (MenACWY-TT) vaccine and its components. Registered for use in people aged ≥6 weeks. MenACWY -TT — quadrivalent meningococcal (serogroups A, C, W, Y)–tetanus toxoid conjugate vaccine. Lyophilised powder in a monodose vial with separate pre-filled syringe or ampoule of solvent. Each 0.5 mL reconstituted dose contains:

Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. From 1 July 2024, Nimenrix will be funded for eligible tamariki under 12 months of age as part of the special group programme.